Home › Research › Brain scans and imaging
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study
Osama Sabri, Marwan Noel Sabbagh, John Peter Seibyl, Henryk Barthel, Hiroyasu Akatsu, Yasuomi Ouchi, 宏平 仙田, Shigeo Murayama, Kenji Ishii, Masaki Takao, Thomas G. Beach, Christopher Cleon Rowe, James B. Leverenz, Bernardino Francesco Ghetti, James W. Ironside, Ana María Catafau, Andrew Wills Stephens, André Mueller, Norman Koglin, Anja Hoffmann, Katrin Sabine Roth, Cornelia B Reininger, Walter Schulz‐Schaeffer, Florbetaben Phase 3 Study Group. Alzheimer s & Dementia, 2015-03-27
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
BACKGROUND: Evaluation of brain β-amyloid by positron emission tomography (PET) imaging can assist in the diagnosis of Alzheimer disease (AD) and other dementias. METHODS: Open-label, nonrandomized, multicenter, phase 3 study to validate the (18)F-labeled β-amyloid tracer florbetaben by comparing in vivo PET imaging with post-mortem histopathology. RESULTS: Brain images and tissue from 74 deceased subjects (of 216 trial participants) were analyzed. Forty-six of 47 neuritic β-amyloid-positive cases were read as PET positive, and 24 of 27 neuritic β-amyloid plaque-negative cases were read as PET negative (sensitivity 97.9% [95% confidence interval or CI 93.8-100%], specificity 88.9% [95% CI 77.0-100%]). In a subgroup, a regional tissue-scan matched analysis was performed. In areas known to strongly accumulate β-amyloid plaques, sensitivity and specificity were 82% to 90%, and 86% to 95%, respectively. CONCLUSIONS: Florbetaben PET shows high sensitivity and specificity for the detection of histopathology-confirmed neuritic β-amyloid plaques and may thus be a valuable adjunct to clinical diagnosis, particularly for the exclusion of AD. TRIAL REGISTRATION: ClinicalTrials.govNCT01020838.
What this study adds
Evidence grade: Not rated
A phase 3 study compared florbetaben PET scans with brain tissue examined after death in 74 people. Scans were read as positive in 46 of 47 cases with amyloid plaques and negative in 24 of 27 cases without, and the authors say the scan may be a valuable adjunct to clinical diagnosis, particularly for ruling out Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Sabri, O., Sabbagh, M. N., Seibyl, J. P., Barthel, H., Akatsu, H., Ouchi, Y., et al. (2015). Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study. Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2015.02.004
Vancouver
Sabri O, Sabbagh MN, Seibyl JP, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study. Alzheimer s & Dementia. 2015. doi:10.1016/j.jalz.2015.02.004. PMID: 25824567.
BibTeX
@article{sabri2015-25824567,
author = {Sabri, Osama and Sabbagh, Marwan Noel and Seibyl, John Peter and Barthel, Henryk and Akatsu, Hiroyasu and Ouchi, Yasuomi and 仙田, 宏平 and Murayama, Shigeo and Ishii, Kenji and Takao, Masaki and Beach, Thomas G. and Rowe, Christopher Cleon and Leverenz, James B. and Ghetti, Bernardino Francesco and Ironside, James W. and Catafau, Ana María and Stephens, Andrew Wills and Mueller, André and Koglin, Norman and Hoffmann, Anja and Roth, Katrin Sabine and Reininger, Cornelia B and Schulz‐Schaeffer, Walter and {Florbetaben Phase 3 Study Group}},
title = {{Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study}},
journal = {Alzheimer s \& Dementia},
year = {2015},
doi = {10.1016/j.jalz.2015.02.004},
pmid = {25824567},
url = {https://doi.org/10.1016/j.jalz.2015.02.004}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 24 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Why it matters
A phase 3 study compared florbetaben PET scans with brain tissue examined after death in 74 people. Scans were read as positive in 46 of 47 cases with amyloid plaques and negative in 24 of 27 cases without, and the authors say the scan may be a valuable adjunct to clinical diagnosis, particularly for ruling out Alzheimer's disease.
New to this subject? Start with our plain-English guide: Brain scans & tests →
How this study scored 53/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on strength of evidence and senior author's track record, so those were left out: it earned 48 of the 91 points we could judge it on, which is 53 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | — / 5 | No evidence rating recorded — left out of this score |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2015 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 604 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 46.5 citations a year over 13 year(s) since 2015 |
| Impact for its field and year | 5 / 6 | Cited 35.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 3 / 4 | Cited 177 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 3 / 3 | University of Washington: institution h-index 3,540 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 21 institution(s) in 5 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 25824567) |
| Free to read | 2 / 2 | Free to read |
| Points | 48 / 91 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 48 of the 91 points we could judge it on is 53 out of 100. |
| Total | 53 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.jalz.2015.02.004
- PubMed: 25824567
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Brain scans and imaging from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.